ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
RBx
|
23 |
9.9K |
5 |
15/05/21 |
15/05/21 |
ASX - By Stock
|
23
|
9.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Exquisite Timing
|
|
RBx
|
23 |
9.9K |
17 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
23
|
9.9K
|
17
|
|
ASX - By Stock
|
NOX |
Exquisite Timing
|
|
RBx
|
23 |
9.9K |
35 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
23
|
9.9K
|
35
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Trial Achieves Full Enrolment
|
|
RBx
|
10 |
4.4K |
15 |
12/05/21 |
12/05/21 |
ASX - By Stock
|
10
|
4.4K
|
15
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
RBx
|
32 |
10K |
4 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda FDA Approved Trial to Commence
|
|
RBx
|
32 |
10K |
14 |
07/05/21 |
07/05/21 |
ASX - By Stock
|
32
|
10K
|
14
|
|
ASX - By Stock
|
NOX |
This is crazy
|
|
RBx
|
24 |
8.4K |
6 |
06/05/21 |
06/05/21 |
ASX - By Stock
|
24
|
8.4K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
CEO Interview 27 April
|
|
RBx
|
15 |
3.6K |
11 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
15
|
3.6K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
Ann: March Quarterly Activities Report and Appendix 4C
|
|
RBx
|
13 |
4.2K |
11 |
27/04/21 |
27/04/21 |
ASX - By Stock
|
13
|
4.2K
|
11
|
|
ASX - By Stock
|
NOX |
Re:
A note from GK
|
|
RBx
|
7 |
2.9K |
7 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
7
|
2.9K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Patent update
|
|
RBx
|
16 |
6.1K |
10 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
16
|
6.1K
|
10
|
|
ASX - By Stock
|
NOX |
Septic sceptic
|
|
RBx
|
0 |
397 |
15 |
23/04/21 |
23/04/21 |
ASX - By Stock
|
0
|
397
|
15
|
|
ASX - By Stock
|
NOX |
Company Maker?
|
|
RBx
|
11 |
3.8K |
28 |
12/04/21 |
12/04/21 |
ASX - By Stock
|
11
|
3.8K
|
28
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda Patent Lodged for Major Septic Shock Opportunity
|
|
RBx
|
16 |
7.6K |
19 |
06/04/21 |
06/04/21 |
ASX - By Stock
|
16
|
7.6K
|
19
|
|
ASX - By Stock
|
NOX |
A GREAT interview by Peter Switzer
|
|
RBx
|
3 |
1.6K |
15 |
24/03/21 |
24/03/21 |
ASX - By Stock
|
3
|
1.6K
|
15
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm IONIC Immuno-Oncology Trial Commences
|
|
RBx
|
14 |
6.1K |
21 |
19/03/21 |
19/03/21 |
ASX - By Stock
|
14
|
6.1K
|
21
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Noxopharm Presents to H.C. Wainwright Global Conference
|
|
RBx
|
2 |
1.9K |
17 |
05/03/21 |
05/03/21 |
ASX - By Stock
|
2
|
1.9K
|
17
|
|
ASX - By Stock
|
NOX |
12 month performance
|
|
RBx
|
1 |
1.5K |
3 |
04/03/21 |
04/03/21 |
ASX - By Stock
|
1
|
1.5K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Option Underwriting Agreement to Secure Funds
|
|
RBx
|
22 |
6.8K |
12 |
21/02/21 |
21/02/21 |
ASX - By Stock
|
22
|
6.8K
|
12
|
|
ASX - By Stock
|
NOX |
CEO LuPIN Blog
|
|
RBx
|
2 |
937 |
30 |
19/02/21 |
19/02/21 |
ASX - By Stock
|
2
|
937
|
30
|
|
ASX - By Stock
|
NOX |
Re:
Ann: LuPIN Survival Outcome Confirmed by Conference Presentation
|
|
RBx
|
25 |
7.4K |
15 |
15/02/21 |
15/02/21 |
ASX - By Stock
|
25
|
7.4K
|
15
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
RBx
|
33 |
10K |
14 |
11/02/21 |
11/02/21 |
ASX - By Stock
|
33
|
10K
|
14
|
|
ASX - By Stock
|
NOX |
GK clarifies IP situation
|
|
RBx
|
4 |
1.7K |
32 |
10/02/21 |
10/02/21 |
ASX - By Stock
|
4
|
1.7K
|
32
|
|
ASX - By Stock
|
NOX |
Re:
LuPIN abstract
|
|
RBx
|
33 |
10K |
13 |
09/02/21 |
09/02/21 |
ASX - By Stock
|
33
|
10K
|
13
|
|
ASX - By Stock
|
NOX |
LuPIN abstract
|
|
RBx
|
33 |
10K |
17 |
30/01/21 |
30/01/21 |
ASX - By Stock
|
33
|
10K
|
17
|
|
ASX - By Stock
|
NOX |
Looking good
|
|
RBx
|
27 |
10K |
12 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
27
|
10K
|
12
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOXCOVID Study Advances
|
|
RBx
|
7 |
3.4K |
9 |
13/01/21 |
13/01/21 |
ASX - By Stock
|
7
|
3.4K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
BMS woes continue
|
|
RBx
|
11 |
3.2K |
2 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
11
|
3.2K
|
2
|
|
ASX - By Stock
|
NOX |
BMS woes continue
|
|
RBx
|
11 |
3.2K |
11 |
07/01/21 |
07/01/21 |
ASX - By Stock
|
11
|
3.2K
|
11
|
|
ASX - By Stock
|
NOX |
What a great update!
|
|
RBx
|
0 |
325 |
8 |
06/01/21 |
06/01/21 |
ASX - By Stock
|
0
|
325
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Competitors
|
|
RBx
|
12 |
4.3K |
6 |
02/01/21 |
02/01/21 |
ASX - By Stock
|
12
|
4.3K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Competitors
|
|
RBx
|
12 |
4.3K |
2 |
01/01/21 |
01/01/21 |
ASX - By Stock
|
12
|
4.3K
|
2
|
|
ASX - By Stock
|
NOX |
GK commentary
|
|
RBx
|
0 |
364 |
8 |
30/12/20 |
30/12/20 |
ASX - By Stock
|
0
|
364
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Strategy
|
|
RBx
|
9 |
3.3K |
9 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
9
|
3.3K
|
9
|
|
ASX - By Stock
|
NOX |
Strategy
|
|
RBx
|
9 |
3.3K |
15 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
9
|
3.3K
|
15
|
|
ASX - By Stock
|
NOX |
Re:
Competitors
|
|
RBx
|
12 |
4.3K |
7 |
29/12/20 |
29/12/20 |
ASX - By Stock
|
12
|
4.3K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Federal Government Approved Future Overseas R&D Expenditure
|
|
RBx
|
5 |
2.1K |
6 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
5
|
2.1K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
large sales
|
|
RBx
|
8 |
3.3K |
9 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
8
|
3.3K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
|
|
RBx
|
11 |
5.1K |
5 |
10/12/20 |
10/12/20 |
ASX - By Stock
|
11
|
5.1K
|
5
|
|
ASX - By Stock
|
NOX |
Misinformation
|
|
RBx
|
2 |
886 |
14 |
10/12/20 |
10/12/20 |
ASX - By Stock
|
2
|
886
|
14
|
|
ASX - By Stock
|
NOX |
Webinar Observations
|
|
RBx
|
14 |
5.1K |
20 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
14
|
5.1K
|
20
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
|
|
RBx
|
11 |
5.1K |
17 |
07/12/20 |
07/12/20 |
ASX - By Stock
|
11
|
5.1K
|
17
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
RBx
|
7 |
2.4K |
6 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
RBx
|
7 |
2.4K |
10 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
7
|
2.4K
|
10
|
|
ASX - By Stock
|
KZA |
VAL-083 updated results
|
|
RBx
|
21 |
6.4K |
6 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
21
|
6.4K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
RBx
|
791 |
218K |
3 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
791
|
218K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
RBx
|
791 |
218K |
1 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
791
|
218K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Efficacy against Septic Shock
|
|
RBx
|
8 |
2.4K |
7 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
8
|
2.4K
|
7
|
|
ASX - By Stock
|
NOX |
Efficacy against Septic Shock
|
|
RBx
|
8 |
2.4K |
10 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
8
|
2.4K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
There is a lot going on
|
|
RBx
|
8 |
2.4K |
8 |
10/11/20 |
10/11/20 |
ASX - By Stock
|
8
|
2.4K
|
8
|
|